Rethinking child treatments

Developing evidence-based treatments - specifically for children

Releases

Releases

29. June, 2021

Cessatech announces new Chairman of the Board – getting ready for the pivotal studies

  The Board of Directors has appointed Adam Steensberg as new Chairman of the...

Read more

Releases

31. May, 2021

Last subject dosed in bioavailability trial 0204 of lead product candidate

Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports...

Read more

Releases

14. May, 2021

Cessatech A/S is awarded IPO of the year 2020 by independent editorial Affärsvärlden

Among the 26 micro-companies, the IPO guide’s reviewers found an average of 2.9 flags....

Read more

Releases

19. April, 2021

First quarter report Q1-2021 – ‘one down, two to go’ of the major milestones of 2021

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...

Read more

Releases

24. March, 2021

Cessatech reports first subject dosed in bioavailability trial of lead product candidate

Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001. Primary...

Read more

Facts about Children

Facts

2. February, 2021

Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner

Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...

Read more

Facts

8. September, 2020

Behov for større sikkerhed omkring medicin til børn og unge i Danmark

Kun 30% af markedsførte lægemidler i EU er godkendt til børn, og kun 50%...

Read more

Facts

31. August, 2020

DR.dk focus – Børn og ældre får medicin, der ikke er godkendt til dem

Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...

Read more

Facts

5. June, 2020

High off-label use in Children

Studies are still needed to determine the safety and efficacy of drugs that lack FDA labeling for this vulnerable patient population. Drugs were administered off-label...

Read more

Facts

1. May, 2020

Children are not small adults

Children differ pharmacokinetically from adults, and medication for adults cannot simply be administered in smaller doses

Read more

Experience

Proven track-record within drug development and product launches, in Europe, US and Asia.

The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.

Team
Lead Asset

CT001 – Nasal spray

Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.

See details

Stay up to date!

Subscribe and get notified on Cessatech's latest news.